Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP638932.RAfuwo_DvMctLbPsXQ0hdQhAZY-TKiz-Bjl8o5-wsUwZg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP638932.RAfuwo_DvMctLbPsXQ0hdQhAZY-TKiz-Bjl8o5-wsUwZg130_assertion type Assertion NP638932.RAfuwo_DvMctLbPsXQ0hdQhAZY-TKiz-Bjl8o5-wsUwZg130_head.
- NP638932.RAfuwo_DvMctLbPsXQ0hdQhAZY-TKiz-Bjl8o5-wsUwZg130_assertion description "[For this reason, farnesyl transferase inhibitors, MAPK inhibitors, Rac guanosine triphosphatase inhibitors, PI3K inhibitors, JAK inhibitors, Hsp90 inhibitors, mTOR inhibitors, PP2A activators and apoptosis inducers have been tested, alone or in combination with ATP-competitive inhibitors, against CML cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP638932.RAfuwo_DvMctLbPsXQ0hdQhAZY-TKiz-Bjl8o5-wsUwZg130_provenance.
- NP638932.RAfuwo_DvMctLbPsXQ0hdQhAZY-TKiz-Bjl8o5-wsUwZg130_assertion evidence source_evidence_literature NP638932.RAfuwo_DvMctLbPsXQ0hdQhAZY-TKiz-Bjl8o5-wsUwZg130_provenance.
- NP638932.RAfuwo_DvMctLbPsXQ0hdQhAZY-TKiz-Bjl8o5-wsUwZg130_assertion SIO_000772 20166937 NP638932.RAfuwo_DvMctLbPsXQ0hdQhAZY-TKiz-Bjl8o5-wsUwZg130_provenance.
- NP638932.RAfuwo_DvMctLbPsXQ0hdQhAZY-TKiz-Bjl8o5-wsUwZg130_assertion wasDerivedFrom befree-20150227 NP638932.RAfuwo_DvMctLbPsXQ0hdQhAZY-TKiz-Bjl8o5-wsUwZg130_provenance.
- NP638932.RAfuwo_DvMctLbPsXQ0hdQhAZY-TKiz-Bjl8o5-wsUwZg130_assertion wasGeneratedBy ECO_0000203 NP638932.RAfuwo_DvMctLbPsXQ0hdQhAZY-TKiz-Bjl8o5-wsUwZg130_provenance.